Scientists Use Inactive Virus to Safe-Deliver Spasticity-Reversing Spinal Genes

Why It Matters

A long‑lasting, localized gene therapy could replace lifelong drug regimens, reducing side effects and healthcare costs for spinal cord injury patients.

Key Takeaways

• Inactive AAV9 vector delivers GAD65 and VGAT genes to spinal neurons
• Treated rats showed progressive spasticity reduction after several weeks
• Gene expression stayed localized; no adverse effects observed up to 4.5 years
• Safety confirmed in pig and non‑human primate models
• Single spinal‑segment injection may replace lifelong spasticity drugs

Pulse Analysis

Muscle spasticity remains one of the most challenging sequelae of spinal cord injury, impairing gait, self‑care and overall quality of life. Conventional pharmacologic regimens—such as baclofen, tizanidine or intrathecal pumps—require chronic dosing, carry systemic side effects, and often lose efficacy over time. The therapeutic gap has spurred interest in approaches that can restore the underlying inhibitory circuitry rather than merely dampening symptoms. In this landscape, a preclinical study published in Molecular Therapy demonstrates a novel gene‑therapy platform that could fundamentally shift how clinicians manage post‑injury tone abnormalities.

The investigators employed an adeno‑associated virus serotype 9 (AAV9) rendered replication‑incompetent to ferry two complementary genes—GAD65, which synthesizes the inhibitory neurotransmitter GABA, and VGAT, the vesicular transporter that packages GABA for release—directly into spinal cord tissue adjacent to the lesion. In a chronic rat model of injury‑induced spasticity, a single subpial injection produced a steady rise in GABAergic signaling, translating into measurable reductions in muscle stiffness and reflex hyperexcitability within weeks. Importantly, biodistribution analyses confirmed confinement of the vector to the targeted segment, and no motor or sensory deficits emerged over a 4.5‑year observation period.

Beyond rodents, the same vector demonstrated safety in both pig and non‑human primate studies, clearing a critical translational hurdle for regulatory approval. If similar durability and specificity are achieved in humans, a one‑time spinal‑segment therapy could supplant daily oral agents, reduce healthcare costs associated with long‑term drug management, and improve patient adherence. The commercial potential is sizable, given the estimated 17,000 new spinal cord injuries annually in the United States alone. Ongoing work will need to address scale‑up manufacturing, immune‑response mitigation, and rigorous clinical trial design to validate efficacy across diverse injury phenotypes.